The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry

On behalf of the PREFER in VTE investigators, Giancarlo Agnelli, Anselm K. Gitt, Rupert Bauersachs, Eva Maria Fronk, Petra Laeis, Patrick Mismetti, Manuel Monreal, Stefan N. Willich, Wolf Peter Wolf, Alexander T. Cohen*, Marianne Brodmann, Peter Rief, Lisbeth Eischer, Slagjana Stoshikj, Michael Hirschl, Serge Weinmann, Peter Marschang, Fabrice Abbadie, Antoine AchkarAzeddine Addala, Frédéric Adnet, Jean François Alexandra, Sandro Aquilanti, Abdelkader Belhassane, Anne Benaroya, Toufek Berremili, Marie Chevallier Grenot, Virginie Birr, Daniela Holtea, Christophe Bonnin, Frederic Bosler, Marie Gabrielle Bresin Durand, Dominique Brisot, Christophe Brousse, Tarodo De La Fuente, Richard Cayman, Michèle Cazaubon, Olivier Champion, Myriam Chanut, Pascal Chevalet, Jerome Connault, Cecile Durant, Joel Constans, Mihaela Cordeanu, Francis Couturaud, Karine Lacut, Laure De Dedker, Eric Decoulx, Benoit Derrien, Matthew Reed

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: Venous thromboembolism (VTE) is a major health problem, with over one million events every year in Europe. However, there is a paucity of data on the current management in real life, including factors influencing treatment pathways, patient satisfaction, quality of life (QoL), and utilization of health care resources and the corresponding costs. The PREFER in VTE registry has been designed to address this and to understand medical care and needs as well as potential gaps for improvement. Methods/design: The PREFER in VTE registry was a prospective, observational, multicenter study conducted in seven European countries including Austria, France Germany, Italy, Spain, Switzerland, and the UK to assess the characteristics and the management of patients with VTE, the use of health care resources, and to provide data to estimate the costs for 12 months treatment following a first-time and/or recurrent VTE diagnosed in hospitals or specialized or primary care centers. In addition, existing anticoagulant treatment patterns, patient pathways, clinical outcomes, treatment satisfaction, and health related QoL were documented. The centers were chosen to reflect the care environment in which patients with VTE are managed in each of the participating countries. Patients were eligible to be enrolled into the registry if they were at least 18 years old, had a symptomatic, objectively confirmed first time or recurrent acute VTE defined as either distal or proximal deep vein thrombosis, pulmonary embolism or both. After the baseline visit at the time of the acute VTE event, further follow-up documentations occurred at 1, 3, 6 and 12 months. Follow-up data was collected by either routinely scheduled visits or by telephone calls. Results: Overall, 381 centers participated, which enrolled 3,545 patients during an observational period of 1 year. Conclusion: The PREFER in VTE registry will provide valuable insights into the characteristics of patients with VTE and their acute and mid-term management, as well as into drug utilization and the use of health care resources in acute first-time and/or recurrent VTE across Europe in clinical practice. Trial registration: Registered in DRKS register, ID number: DRKS00004795

Original languageEnglish
Article number41
JournalThrombosis Journal
Issue number1
Publication statusPublished - 21 Oct 2015


  • Anticoagulation
  • Novel Oral Anticoagulants
  • Prevention
  • Registry
  • Venous Thromboembolism
  • Vitamin K antagonists


Dive into the research topics of 'The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry'. Together they form a unique fingerprint.

Cite this